Home › Respiratory Distress Syndrome › NCT06690801
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Who can join
Ages 0 to 21 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age \>37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent. * Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV. * Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples. Exclusion Criteria: * Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission * ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission * Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team) * Air leak \>20% (endotracheal tube, tracheostomy tube, or thoracostomy tube) * Home Invasive Mechanical Ventilation * Cyanotic Congenital Heart Disease * Previous enrollment in the DiNO study * Do not resuscitate order at the time of pediatric ARDS diagnosis. * Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.
About the study
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS).
The study aims are:
1. To validate AVDSf for risk stratification of mortality in pediatric ARDS 2. To determine if there is heterogeneity in treatment effect for iNO defined by AVDSf 3. To detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies this association
This is a prospective, multicenter observational study of 1260 mechanically ventilated children with moderate to severe ARDS. In a subgroup of 450 children with severe ARDS, longitudinal blood samples will be obtained to measure plasma protein markers.
Sponsor: Children's Hospital Los Angeles · Participants: 1,260 · Started: Oct 3, 2024
Contact the study team
- Jeni Kwok · Phone: 3233617939
- Anoopindar Bhalla, MD · Phone: 3233617939
Official record on ClinicalTrials.gov — NCT06690801
Locations in the U.S.
| California | Children's Hospital Los Angeles, Los Angeles |
| Colorado | Children's Hospital Colorado, Denver (Not yet recruiting) |
| Massachusetts | Boston Children's Hospital, Boston (Not yet recruiting) |
| Nebraska | University of Nebraska Medical Center / Children's Hospital and Medical Center, Omaha (Not yet recruiting) |
| Ohio | Cincinnati Children's Hospital Medical Center, Cincinnati (Not yet recruiting) |
| Pennsylvania | Children's Hospital of Philadelphia, Philadelphia (Not yet recruiting) |
| Texas | Texas Children's Hospital Baylor College of Medicine, Houston (Not yet recruiting) |
| Wisconsin | American Family Children's Hospital / University of Wisconsin-Madison, Madison (Not yet recruiting) Children's Hospital of Wisconsin / Medical College of Wisconsin, Milwaukee (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.